Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia

Health Services Research

Volumn 33, Issue 5 I, 1998, Pages 1237-1261

  Rosenheck, Robert ^a   Cramer, Joyce ^a   Xu, Weichun ^a   Grabowski, John ^a   Douyon, Richard ^a   Thomas, Jonathan ^a   Henderson, William ^a   Charney, Dennis ^a  

^a NONE

Author keywords

Clinical trial; Clozapine; Cost effectiveness; Pharmacoeconomics; Schizophrenia

Indexed keywords

CLOZAPINE; HALOPERIDOL;

ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG POTENCY; HUMAN; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; QUALITY ADJUSTED LIFE YEAR; SCHIZOPHRENIA;

CLOZAPINE; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; DRUG COSTS; HALOPERIDOL; HOSPITAL COSTS; HOSPITALS, VETERANS; HUMANS; LONG-TERM CARE; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT ADMISSION; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; QUALITY-ADJUSTED LIFE YEARS; SCHIZOPHRENIA;

EID: 0032443704     PISSN: 00179124     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Alvir, J. M., J. A. Lieberman, A. Z. Safferman, J. L. Schwimmer, and J. Schaaf. 1993. "Clozapine-induced Agranulocytosis: Incidence and Risk Factors in the United States." The New England Journal of Medicine 329 (3): 162-67.
2. Barnes, T. R. E. 1989. "A Rating Scale for Drug Induced Akathisia." British Journal of Psychiatry 131 (3): 222-23.
3. Carpenter, W. T., R. R. Conley, R. W. Buchanan, A. Breier, and C. Tamminga. 1996. "Patient Response and Resource Management: Another View of Clozapine Treatment of Schizophrenia." American Journal of Psychiatry 152 (6): 827-32.
4. Cohen, J. 1969. Statistical Power Analysis for the Behavioral Sciences. New York: Academic Press.
5. Detsky, A. S. 1996. "Evidence of Effectiveness." In Valuing Health Care, edited by F. A. Sloan. New York: Cambridge University Press.
6. Essock, S. M., W. A. Hargreaves, N. H. Covell, and J. Goethe. 1996. "Clozapine's Effectiveness for Patients in State Hospitals: Results from a Randomized Trial." Psychopharmacology Bulletin 32 (4): 683-97.
7. Gibbons, R. D., D. Hedeker, and J. Elkin. 1993. "Some Conceptual and Statistical Issues in Analysis of Longitudinal Psychiatric Data." Archives of General Psychiatry 50 (9): 739-50.
8. Gold, M. R., J. E. Siegel, L. B. Russell, and M. C. Weinstein. 1996. Cost Effectiveness in Health and Medicine. New York: Oxford University Press.
9. Guy, W. 1976. "Abnormal Involuntary Movements." In ECDEU Assessment Manual for Psychopharmacology, edited by W. Guy. Department of Health, Education, and Welfare, Pub. No. (ADM) 76-338. Rockville, MD: National Institute of Mental Health.
10. Hargreaves, W. A., M. Shumway, T. W. Hu, and B. Cuffel. 1998. Cost-Outcome Methods for Mental Health. San Diego, CA: Academic Press.
11. Heinrichs, D. W., E. T. Hanlon, and W. T. Carpenter. 1984. "The Quality of Life Scale: An Instrument for Rating the Schizophrenic Deficit Syndrome." Schizophrenia Bulletin 10 (3): 388-98.
12. Kane, J. M., and S. R. Marder. 1993. "Psychopharmacologic Treatment of Schizophrenia." Schizophrenia Bulletin 19 (2): 287-302.
13. Kane, J. M., G. Honigfeld, J. Singer, and H. Y. Meltzer, and the Clozaril Collaborative Study Group. 1988. "Clozapine for the Treatment-Resistant Schizophrenic: A Double Blind Comparison with Chlorpromazine." Archives of General Psychiatry 45 (9): 789-96.
14. Kaplan, R. M. 1996. "Utility Assessment for Estimating Quality-Adjusted Life Years." In Valuing Health Care, edited by F. A. Sloan. New York: Cambridge University Press.
15. Kay, S. R., A. Fiszbeing, and D. R. Opler. 1987. "The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia." Schizophrenia Bulletin 13 (2): 261-76.
16. Kleinman, L. S. 1995. "Preferences for Outpatient Mental Health Treatment." Ph.D. Thesis, Johns Hopkins University, School of Hygiene and Public Health.
17. Lehman, A. F. 1988. "A Quality of Life Interview for the Chronically Mentally Ill." Evaluation and Program Planning 11 (1): 51-62.
18. Meltzer, H. Y. 1992. "Treatment of the Neuroleptic-Nonresponsive Schizophrenic Patient." Schizophrenia Bulletin 18 (3): 515-42.
19. Meltzer, H. Y., P. Cola, and L. Way. 1993. "Cost-Effectiveness of Clozapine in Neuroleptic Resistant Schizophrenia." American Journal of Psychiatry 150 (11): 1630-38.
20. O'Brien, B. J., M. F. Drummond, R. Labelle, and A. Willan. 1994. "In Search of Power and Significance: Issues in the Design and Analysis of Stochastic Cost-Effectiveness Studies in Health Care." Medical Care 32 (2): 150-63.
21. Office of the Inspector General. 1992. Comparison of Costs and Outcomes of Matched Pairs of VAMCs and Their University Affiliates. Washington, DC: Office of the Inspector General.
22. Reid, W. H., M. Mason, and M. Toprac. 1994. "Savings in Hospital Bed-Days Related to Treatment with Clozapine." Hospital and Community Psychiatry 45 (3): 261-68.
23. Revicki, D. A., A. Shakespeare, and P. Kind. 1996. "Preferences for Schizophrenia-related Health States: A Comparison of Patients, Caregivers and Psychiatrists." International Clinical Psychopharmacology 11 (2): 101-108.
24. Rosenheck, R. A., D. Evans, L. Herz, J. A. Cramer, W. Xu, J. Thomas, W. Henderson, and D. Charney. In press. "How Long to Wait for a Response to Clozapine? A Comparison of Time Course of Response to Clozapine and Conventional Antipsychotic Medication in Refractory Schizophrenia." Schizophrenia Bulletin.
25. Rosenheck, R. A., J. Cramer, W. Xu, J. Thomas, W. Henderson, L. K. Frisman, C. Fye, and D. Charney, for the Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. 1997. "A Comparison of Clozapine and Haloperidol in the Treatment of Hospitalized Patients with Refractory Schizophrenia." The New England Journal of Medicine 337 (12): 809-13.
26. Rupp, A., and S. J. Keith. 1993. "The Costs of Schizophrenia." Psychiatric Clinics of North America 16 (2): 413-23.
27. Simpson, G. M., and J. W. S. Angus. 1970. "A Rating Scale for Extrapyramidal Side Effects." Acta Psychiatry Scandanavica 212 (Supplement): 11-19.
28. Spilker, B., ed. 1996. Quality of Life and Pharmacoeconomics in Clinical Trials, 2d ed. Philadelphia, PA: Lippincott-Raven.
29. Weinstein, M. C. 1996. "From Cost-Effectiveness Ratios to Resource Allocation: Where to Draw the Line." In Valuing Health Care, edited by F. A. Sloan. New York: Cambridge University Press.